- ISIN
- US29664W1053
- CUSIP
- 29664W105
- Delisting Date
- Jul 14, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 26, 2013
Highlights
- Market Cap
- $661.15M
- Enterprise Value
- $759.32M
- EPS (TTM)
- -$0.03
- Total Revenue (TTM)
- $418.24M
- Gross Profit (TTM)
- $226.32M
- EBITDA (TTM)
- $77.18M
- Year Range
- $1.13 - $4.18
- Target Price
- $3.19
- ROA (TTM)
- -1.60%
- ROE (TTM)
- 2.41%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ESPR Performance Chart
Loading charts...
Compare this symbol against anything
Returns By Period
Esperion Therapeutics, Inc. (ESPR) has returned -14.05% so far this year and 127.14% over the past 12 months. Over the last ten years, ESPR has returned -11.79% per year, falling short of the S&P 500 Index benchmark, which averaged 13.29% annually.
Esperion Therapeutics, Inc.
- 1D
- 0.00%
- 1M
- 0.63%
- 6M
- -9.14%
- YTD
- -14.05%
- 1Y
- 127.14%
- 3Y*
- 30.22%
- 5Y*
- -29.19%
- 10Y*
- -11.79%
- ALL TIME*
- -12.06%
Benchmark (S&P 500 Index)
- 1D
- 1.48%
- 1M
- 1.57%
- 6M
- 8.95%
- YTD
- 11.03%
- 1Y
- 21.84%
- 3Y*
- 19.28%
- 5Y*
- 11.54%
- 10Y*
- 13.29%
- ALL TIME*
- 8.11%
ESPR Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.38% | -1.18% | -18.21% | -27.01% | 56.50% | 0.96% | 0.63% | -14.05% | |||||
| 2025 | -18.64% | -5.03% | -15.29% | -30.60% | -14.97% | 15.84% | 44.25% | 56.34% | 19.37% | 12.08% | 35.02% | -7.73% | 68.18% |
| 2024 | -28.43% | 17.29% | 6.77% | -26.49% | 9.64% | 2.78% | 4.05% | -20.78% | -9.84% | 23.64% | 37.25% | -21.43% | -26.42% |
| 2023 | 2.09% | -2.83% | -74.27% | -16.98% | 3.03% | 2.21% | 12.95% | 1.91% | -38.75% | -15.43% | 60.47% | 124.81% | -52.01% |
| 2022 | -14.20% | -4.66% | 13.45% | 22.41% | 0.35% | 11.58% | -9.28% | 29.29% | -10.19% | 21.34% | -17.59% | -7.01% | 24.60% |
| 2021 | 21.12% | -13.02% | 2.41% | -3.92% | -26.12% | 6.23% | -27.23% | -15.40% | -7.45% | -25.81% | -2.35% | -42.73% | -80.77% |
Benchmark Metrics
Esperion Therapeutics, Inc. has an annualized alpha of 6.51%, beta of 1.23, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since June 26, 2013.
- This stock participated in 144.61% of S&P 500 Index downside but only 35.40% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 6.51%
- Beta
- 1.23
- R²
- 0.06
- Upside Capture
- 35.40%
- Downside Capture
- 144.61%
Return for Risk
Risk / Return Rank
ESPR ranks 89 for risk / return — above 89% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Esperion Therapeutics, Inc. (ESPR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ESPR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.16 | ||
| Sortino ratioReturn per unit of downside risk | +0.59 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.31 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | 3.16 | 2.41 | +0.75 |
| Martin ratioReturn relative to average drawdown | 7.64 | 10.22 | -2.58 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Esperion Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Esperion Therapeutics, Inc. was 99.37%, occurring on May 14, 2025. The portfolio has not yet recovered.
The current Esperion Therapeutics, Inc. drawdown is 97.24%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.37%May 2025 | 9y 12mo | — | 11y 2moMay 2015 - now | 2025 selloff2025 |
-41.24%Nov 2013 | 1mo 24d | 10mo 4d | 11mo 28dOct 2013 - Sep 2014 | — |
-28.66%Oct 2014 | 7d | 15d | 22dOct 2014 - Oct 2014 | — |
-22.60%Mar 2015 | 1d | 1mo 25d | 1mo 26dMar 2015 - May 2015 | — |
-18.82%Sep 2013 | 1mo 5d | 16d | 1mo 21dAug 2013 - Sep 2013 | — |
Drawdown Indicators
| ESPR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.37% | -56.78% | -42.59% |
Max Drawdown (1Y)Largest decline over 1 year | -53.19% | -9.10% | -44.09% |
Max Drawdown (3Y)Largest decline over 3 years | -80.94% | -18.90% | -62.04% |
Max Drawdown (5Y)Largest decline over 5 years | -95.13% | -25.43% | -69.70% |
Max Drawdown (10Y)Largest decline over 10 years | -99.10% | -33.92% | -65.18% |
Current DrawdownCurrent decline from peak | -97.24% | -0.12% | -97.12% |
Average DrawdownAverage peak-to-trough decline | -70.15% | -10.70% | -59.45% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.98% | 2.14% | +19.84% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Esperion Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Esperion Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ESPR relative to other companies in the Biotechnology industry. Currently, ESPR has a P/S ratio of 1.9. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ESPR
Add Esperion Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ESPR